Physician profile
Biswarup Syam
NPI 1942299771
$5,580.82
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $995 · 2021: $1,574 · 2022: $1,037 · 2023: $697 · 2024: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $996 · Education: $28.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $996.48 |
| Education | $28.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,831.20 | 2019-2024 | Mavyret, Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,068.02 | 2019-2024 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $559.47 | 2019-2024 | Entyvio |
| Celgene Corporation | $292.53 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $268.52 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Gilead Sciences, INC. | $246.06 | 2019-2023 | |
| Pfizer INC. | $241.52 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $217.38 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $145.07 | 2021-2023 | |
| Braintree Laboratories, INC. | $120.03 | 2019-2023 | Sutab |
| Evoke Pharma, INC. | $81.90 | 2021-2022 | |
| Ardelyx, INC. | $52.19 | 2024 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $52.04 | 2022-2023 | Dupixent |
| Ironwood Pharmaceuticals, INC | $50.19 | 2019-2023 | Linzess |
| Boston Scientific Corporation | $42.96 | 2023 | Orca, Exalt Model D |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ambu INC. | $39.53 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $30.76 | 2021-2022 | |
| Celltrion USA INC. | $28.60 | 2024 | Yuflyma |
| Genzyme Corporation | $24.50 | 2022 | |
| Fujifilm Healthcare Americas Corporation | $23.38 | 2023 | Fujifilm |
| Amgen INC. | $23.14 | 2022 | |
| Organon LLC | $21.36 | 2023 | Renflexis |
| Allergan, INC. | $19.29 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.91 | 2023 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.52 | 2023 | Cyltezo |
| Lilly USA, LLC | $17.57 | 2024 | Omvoh |
| Merck Sharp & Dohme LLC | $16.75 | 2024 | |
| Qol Medical, LLC | $15.59 | 2019 | |
| Cook Medical LLC | $13.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Biswarup Syam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.